Windtree Fails Nasdaq Bid Price Requirement Faces Delisting August 21

Windtree Therapeutics is on the verge of being delisted from the Nasdaq Capital Market after failing to maintain the minimum $1 bid price requirement for 30 consecutive business days. On August 19, 2025, Nasdaq notified the company of the delisting under Listing Rule 5550(a)(2), as disclosed in SEC filings. Trading in Windtree’s common stock will cease on August 21, 2025, and the company will move to over-the-counter (OTC) trading [1].

The announcement followed a sharp decline in the company’s share price, which plummeted by 77.21% in response to the delisting notice. Year-over-year, shares have fallen nearly 99.98%, reflecting a severe erosion in investor confidence. This delisting is part of a broader trend where companies failing to meet Nasdaq’s continued listing standards face significant liquidity challenges and market visibility loss [3].

Despite raising $60 million in recent securities subscriptions and announcing a $520 million BNB financing deal, Windtree reported a net loss of $10.64 million. The company has not disclosed the extent of institutional participation in these funding activities, leaving questions about the sustainability of its financial strategy. The firm’s treasury management strategy involving BNB has drawn attention but has not been shown to affect the broader cryptocurrency market [6].

Windtree previously regained compliance with Nasdaq’s minimum bid price requirement in March 2025, temporarily avoiding delisting. However, a subsequent sharp decline in its stock price led to renewed noncompliance. The company had also executed a 1-for-50 reverse stock split in an attempt to elevate the share price. Despite these measures, it has failed to maintain compliance [8].

The delisting raises broader concerns about the viability of small biotechnology firms, particularly those with limited revenue and high operational costs. Windtree’s financial profile—marked by zero revenue and a negative P/E ratio—underscores the fragility of its business model. Technical indicators like an RSI of 16.8 and a MACD of -0.08 suggest a continuation of bearish momentum in the near term [7].

Although the company will continue to file with the SEC and assert compliance with all required disclosures, the delisting is expected to limit institutional interest and reduce the liquidity of its shares. Windtree has not issued public statements from its leadership, focusing instead on formal SEC filings and regulatory updates [1].

The firm’s delisting highlights the risks inherent in investing in small-cap biotech companies, especially those operating in capital-intensive and highly regulated environments. The transition to OTC trading may lead to further volatility and could deter new investors from entering the market [4]. The company’s future will largely depend on its ability to stabilize its financial position or secure strategic partnerships that can provide long-term capital and growth opportunities [12].

Source:

[1] https://coinmarketcap.com/community/articles/68a688294b03e574f343574a/

[3] https://cryptoslate.com/bnb-treasury-company-faces-delisting-from-nasdaq-on-aug-21/

[4] https://www.ainvest.com/news/windtree-therapeutics-plunges-64-5-fueling-otc-exodus-2508/

[8] https://www.stocktitan.net/sec-filings/WINT/10-q-windtree-therapeutics-inc-quarterly-earnings-report-1cada8381b60.html